PO.ADV02 · 患者倡导
2009-2025年加拿大各地以及加拿大与美国之间精准肿瘤学药物可及性的差异
Disparities in access to precision oncology drugs across Canada and between Canada and the US, 2009-2025
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
在一项名为"研究中的患者之声"（Patient Voices in Research）的独特资助计划中，希望马拉松癌症中心网络（Marathon of Hope Cancer Centres Network, MOHCCN）邀请了来自加拿大各地的一组患者制定研究议程主题并遴选成功的申请者。其中一个主题是精准医疗可及性方面的公平与差异。我作为一名幸存者研究者参与了一项被选中的研究，该研究系统性地记录了加拿大新型癌症药物的审批过程，以及加拿大与美国之间及加拿大各省之间可及性方面的差异。加拿大癌症患者常常通过FDA已批准某种药物在美国使用的公告而得知新的肿瘤学药物。由于加拿大有其自己的药物审批流程，在美国获批的药物在加拿大可能无法获得。此外，加拿大每个省决定其健康计划下资助哪些药物。我们的研究团队由金斯顿安大略省女王大学（Queen's University）的肿瘤科医生Bishal Gyawali领导，开展了一项回顾性队列研究，考察了2009年至2025年间FDA和加拿大卫生部（Health Canada）对成人实体瘤的审批，以识别延误发生的环节。关键变量为审批时间、资助决策时间以及有效抗癌药物的可及性。我们基于经过验证的ESMO临床获益量表（ESMO-Magnitude of Clinical Benefit Scale）计算了每种药物的临床获益幅度，以评估这些延误是否可能影响患者结局。我的海报凸显了关键研究发现，以及如何将其应用于政策以应对患者对癌症药物可及性不公平的关切。
查看英文原文 English abstract
In a unique funding initiative called Patient Voices inResearch, the Marathon of Hope Cancer Centres Network (MOHCCN) asked a group ofpatients from across Canada to develop themes for a research agenda and toselect the successful applicants. One theme was equity and disparities inaccess to precision medicine. I was a survivor-investigator in a study selectedto systematically document the approval process for new cancer drugs in Canadaand disparities in access between Canada and the U.S. and among provinceswithin Canada. Canadian cancer patients often hear about new oncology drugsthrough announcements that the FDA has approved a drug for use in the U.S.Because Canada has its own drug approval process, a drug approved in the U.S.may not be available in Canada. Furthermore, each Canadian province decideswhich drugs to fund under its health plan. Our research team, led by oncologistBishal Gyawali at Queen's University in Kingston Ontario, conducted aretrospective cohort study of adult solid-cancer approvals by the FDA andHealth Canada from 2009 to 2025 to identify where delays happen. Criticalvariables were time to approval, time to funding decision, and availability ofeffective anti-cancer drugs. We calculated the magnitude of clinical benefit foreach drug based on the validated ESMO-Magnitude of Clinical Benefit Scale toassess whether the delays would likely affect patient outcomes. My posterhighlights key research findings and how they can be applied to policies toaddress patients' concerns about inequities in access to cancer drugs.